(Q53086691)

11 May 2018

title

Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. (English)

1 reference

11 May 2018

1 reference

3

1 reference

11 May 2018

Susan L. Cohn

10

1 reference

11 May 2018

Alberto Garaventa

object named as

Alberto Garaventa

7

0 references

Wendy B London

2

object named as

Wendy B London

1 reference

11 May 2018

Katherine K Matthay

4

object named as

Katherine K Matthay

1 reference

11 May 2018

author name string

Holly J Meany

1

1 reference

11 May 2018

Tom Monclair

5

1 reference

11 May 2018

Thorsten Simon

6

1 reference

11 May 2018

Frank Berthold

8

1 reference

11 May 2018

Akira Nakagawara

9

1 reference

11 May 2018

Andrew D J Pearson

11

1 reference

11 May 2018

Julie R Park

12

1 reference

11 May 2018

publication date

7 July 2014

1 reference

11 May 2018

published in

Pediatric Blood & Cancer

1 reference

11 May 2018

volume

61

1 reference

11 May 2018

issue

11

1 reference

11 May 2018

page(s)

1932-1939

1 reference

11 May 2018

Neuroblastoma: biology, prognosis, and treatment

cites work

1 reference

International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age.

21 January 2018

1 reference

Management and outcome of stage 3 neuroblastoma

21 January 2018

1 reference

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma

21 January 2018

1 reference

Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.

21 January 2018

1 reference

Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group

21 January 2018

1 reference

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

21 January 2018

1 reference

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

21 January 2018

1 reference

Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project

21 January 2018

1 reference

Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis

21 January 2018

1 reference

Chromosome 1p and 11q deletions and outcome in neuroblastoma

21 January 2018

1 reference

Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.

21 January 2018

1 reference

Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project

21 January 2018

1 reference

Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group

21 January 2018

1 reference

[Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study]

21 January 2018

1 reference

Prognostic impact of gene expression-based classification for neuroblastoma.

21 January 2018

1 reference

Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature

21 January 2018

1 reference

MYCN amplification remains prognostically strong 20 years after its “clinical debut”

21 January 2018

1 reference

Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma WithoutMYCNAmplification: Results of the Prospective INES 99.1

21 January 2018

1 reference

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.25134

1 reference

11 May 2018

1 reference

11 May 2018